Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 4592

How we got to where we are today, and where we go from here. Featuring Dr. Daniel Monti (Director — Marcus Institute of Integrative Health) and leading neuroscientist Dr. Andrew Newberg (DMT: The Spirit Molecule), we get a fresh perspective on the effects of stress. Thanks to a new study from the Marcus Institute of Integrative Health at Thomas Jefferson University in Philadelphia, PA, there is now compelling evidence that this breakthrough intervention can help people to alleviate their emotional stress, as well as deeper insight into this exciting topic.

https://stresseddoc.com/

Read more | >

Himanshu Brahmbhatt was staring at the results of a clinical trial that looked too good to be true. A co-founder and CEO of EnGeneIC, a biopharmaceutical company, Brahmbhatt was running a small trial that was testing a fundamentally different approach to fighting cancer. Patients in the group had grim prospects. They had exhausted all other options. With nothing left to lose and not expecting any miracles, they enrolled in the trial. They wanted to give it one more chance. Now their scans showed their tumors had stopped progressing. Even more remarkable was they didn’t have the same type of tumors. They had malignancies affecting different organs—lungs, bladders, colons, pancreases—and yet, they uniformly did well.

“These people were facing death,” Brahmbhatt says. “Then we started seeing that they were actually succeeding. You could see in the scan that the tumor has stopped growing. It was a feeling of such extreme internal joy that it’s very difficult to describe.”

The results may have appeared miraculous, but they were anything but. They stemmed from fundamental research into cell division that forms the basis of the EnGeneIC process. A longtime advisor to the company, Bruce Stillman, professor of biochemistry and president and CEO of Cold Spring Harbor Laboratory, has been studying the process of DNA replication, which plays a key role in cell division and cancer progression.

Read more | >

The end of classical Computer Science is coming, and most of us are dinosaurs waiting for the meteor to hit.

I came of age in the 1980s, programming personal computers like the Commodore VIC-20 and Apple ][e at home. Going on to study Computer Science in college and ultimately getting a PhD at Berkeley, the bulk of my professional training was rooted in what I will call “classical” CS: programming, algorithms, data structures, systems, programming languages. In Classical Computer Science, the ultimate goal is to reduce an idea to a program written by a human — source code in a language like Java or C++ or Python. Every idea in Classical CS — no matter how complex or sophisticated — from a database join algorithm to the mind-bogglingly obtuse Paxos consensus protocol — can be expressed as a human-readable, human-comprehendible program.

When I was in college in the early ’90s, we were still in the depth of the AI Winter, and AI as a field was likewise dominated by classical algorithms. My first research job at Cornell was working with Dan Huttenlocher, a leader in the field of computer vision (and now Dean of the MIT School of Computing). In Dan’s PhD-level computer vision course in 1995 or so, we never once discussed anything resembling deep learning or neural networks—it was all classical algorithms like Canny edge detection, optical flow, and Hausdorff distances. Deep learning was in its infancy, not yet considered mainstream AI, let alone mainstream CS.

Read more | >

Two groundbreaking studies recently published in the journals Nature and Genome Medicine found genetic signatures that explain ethnic disparities in the severity of prostate cancer, notably in Sub-Saharan Africa.

By genetically analyzing prostate cancer tumors from Australian, Brazilian, and South African donors, the team developed a new prostate cancer taxonomy (classification scheme) and cancer drivers that not only distinguish patients based on their genetic ancestry but also predict which cancers are likely to become life-threatening, a task that is currently difficult.

“Our understanding of prostate cancer has been severely limited by a research focus on Western populations,” said senior author Professor Vanessa Hayes, genomicist and Petre Chair of Prostate Cancer Research at the University of Sydney’s Charles Perkins Centre and Faculty of Medicine and Health in Australia. “Being of African descent, or from Africa, more than doubles a man’s risk for lethal prostate cancer. While genomics holds a critical key to unraveling contributing genetic and non-genetic factors, data for Africa has till now, been lacking.”

Read more | >

The Energean company announced to the Tel Aviv and London stock exchanges Thursday that its Hermes exploration well in Israeli maritime waters has yielded a new commercial gas discovery of 7–15 billion cubic meters, according to estimates.

Hermes is located southeast of the Karish field, to which the UK-Greek company holds the production rights.

The Stena IceMax drilling rig has now moved to the so-called Olympus area, located between Energean’s Karish and Tanin fields. The company hopes that exploration will enable it to further refine estimates of natural gas there, which currently stand at a theoretical 58 billion cubic meters, according to Energean’s notice.

Read more | >

Tesla (TSLA) has been officially upgraded to investment grade long-term credit rating by S&P Global Ratings.

Despite delivering profits for more than two years straight and building a cash position of over $18 billion while sitting on very little debt, Tesla was still rated as a “junk bond” by rating companies like S&P Global Ratings and Moody’s Investors Service.

Earlier this year, we reported that the rating agencies are finally changing their opinion on the electric automaker and considering upgrading their ratings.

Read more | >